Core Viewpoint - The government of Lanzhou City has decided to expropriate assets belonging to Zhongmu Co., Ltd., including land, buildings, and equipment from its Lanzhou Biological Pharmaceutical Factory and its wholly-owned subsidiary, Lanzhou Zhongmu Pharmaceutical and Medical Technology Co., Ltd. The total assessed value of the expropriated assets is 229 million yuan [1]. Group 1 - The expropriation involves state-owned land, buildings, and production equipment located at No. 2 Yanchang Road, Chengguan District, Lanzhou City [1]. - The expropriation process will be organized by the Housing and Urban-Rural Development Bureau of Chengguan District and will involve the local street office in charge of compensation and resettlement work [1]. - The assets being expropriated are currently in a state of idleness [1]. Group 2 - The assessed value of the expropriated assets, as evaluated by Gansu Fangjia Real Estate Asset Appraisal Co., Ltd., amounts to 22.9 million yuan [1].

Core Viewpoint - The animal health sector experienced a rise of 1.59% on September 26, with Bio-Pharmaceuticals leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 0.65% and 1.76% respectively [1] Group 1: Market Performance - The animal health sector's individual stock performance showed significant variations, with Bio-Pharmaceuticals closing at 9.34, up by 7.23%, and a trading volume of 1.0367 million shares, resulting in a turnover of 973 million yuan [1] - Other notable performers included Huisheng Biological at 20.68, up by 1.87%, and Ruipu Biological at 20.93, up by 1.60% [1] Group 2: Capital Flow - The animal health sector saw a net inflow of 86.5157 million yuan from institutional investors, while retail investors experienced a net outflow of 44.7995 million yuan [2] - The capital flow data indicates that major stocks like Bio-Pharmaceuticals had a net inflow of 12.63% from institutional investors, despite a significant outflow from retail and speculative investors [3]

Market Overview - On September 25, the animal health sector declined by 1.62% compared to the previous trading day, with the leading stock, Driveline, experiencing a drop of 4.04% [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - The following stocks in the animal health sector showed notable declines: - Driveline (Code: 838275) closed at 9.50, down 4.04% with a trading volume of 19,300 lots [1] - Shunlian Bio (Code: 688098) closed at 10.43, down 3.43% with a trading volume of 76,300 lots [1] - Yongshun Bio (Code: 839729) closed at 9.74, down 2.89% with a trading volume of 20,800 lots [1] - Other notable declines include *ST Green Health (Code: 002868) down 2.39% and Shoufeng Holdings (Code: 002141) down 2.33% [1] Capital Flow - The animal health sector saw a net outflow of 113 million yuan from institutional investors, while retail investors experienced a net inflow of 61.16 million yuan [1] - The following stocks had significant capital flow: - Zhongmu Co. (Code: 600195) had a net inflow of 986,800 yuan from institutional investors [2] - Pulaike (Code: 603566) saw a net inflow of 764,200 yuan from retail investors [2] - *ST Green Health (Code: 002868) experienced a net outflow of 6.71 million yuan from institutional investors [2]

Core Viewpoint - *ST Green Kang announced plans to sell 100% equity stakes in Green Kang Yushan, Green Kang Haining, and Green Kang New Energy to Rao Xin New Energy for a cash transaction, with an overall valuation of 0 yuan due to significant losses impacting the company's overall performance [1][2][3]. Group 1: Transaction Details - The transaction involves the sale of three subsidiaries: Green Kang Yushan, Green Kang Haining, and Green Kang New Energy, with a total valuation of 0 yuan [2]. - The assessment of the subsidiaries revealed substantial losses, with Green Kang Yushan reporting net profits of -55.92 million yuan and -203.25 million yuan for 2023 and 2024 respectively, and Green Kang Haining reporting -21.49 million yuan and -150.73 million yuan for the same years [5]. Group 2: Industry Context - The photovoltaic industry has experienced rapid demand growth for terminal installations, leading to accelerated capacity expansion and increased competition, resulting in a mismatch between supply and demand [4]. - The overall decline in product sales prices has led to reduced profitability for many companies in the industry, with most experiencing operational losses [4]. Group 3: Strategic Shift - *ST Green Kang aims to divest from the severely loss-making photovoltaic film business to focus on its animal protection business, thereby solidifying its core operations [6]. - The company previously operated with a dual business model of animal protection products and photovoltaic film products, but the poor performance of the latter has pressured overall profitability [5].

证券日报网讯 9月24日晚间，金河生物发布公告称，公司于2025年8月18日召开第六届董事会第二十九 次会议、第六届监事会第二十四次会议，审议通过《关于注销2024年股票期权激励计划部分股票期权的 议案》。根据相关规定，鉴于《激励计划》授予的激励对象中3名在职激励对象2024年度个人绩效考核 结果为差，前述激励对象已获授但尚未行权的合计17.50万份股票期权由公司予以注销。2025年9月24 日，经中国证券登记结算有限责任公司深圳分公司审核确认，上述17.50万份股票期权的注销事宜已办 理完成。 （编辑 任世碧） ...

Core Viewpoint - The animal health sector experienced a decline of 1.49% on September 24, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index up by 0.83% and the Shenzhen Component Index up by 1.8% [1][2]. Group 1: Market Performance - The animal health sector's decline was primarily driven by *ST Lvkang, which closed at 28.00, down by 1.16% [2]. - The sector's individual stock performance varied, with notable gainers including Yongshun Biological (+3.72%) and Shilian Biological (+1.69%) [1][2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector showed significant activity, with Yongshun Biological recording a volume of 24,700 hands and a transaction value of 24.36 million [1]. - The sector saw a net outflow of 75.79 million from institutional investors, while retail investors contributed a net inflow of 42.98 million [2][3]. Group 3: Individual Stock Capital Flow - *ST Lvkang experienced a significant net outflow of 10.63 million from institutional investors, indicating a negative sentiment towards the stock [3]. - Conversely, Shilian Biological had a net inflow of 10.41 million from institutional investors, reflecting stronger institutional interest [3].

Core Insights - The report indicates a narrowing profitability in pig farming while the pet food sector continues to grow [1][5] - The investment rating is maintained as "positive" for the sector [1] Pig Farming - Supply pressure has led to a decline in pig prices, with the average price in July-August 2025 at 14.63 CNY/kg, down from 14.96 CNY/kg in Q2 2025 [5] - The average profitability for self-breeding and purchased piglets in the industry has shifted to losses, with figures of 53.0 CNY/head for self-breeding and -106.7 CNY/head for purchased piglets as of September 19 [5] - The outflow of pigs from listed companies has shown a growth rate of 26.2% in Q2 2025 and 20.0% in July-August 2025 [5] - The report suggests that the ongoing policy guidance for capacity adjustment and weight reduction will likely elevate the price center of pigs in the future [5] - Recommended companies for investment include Muyuan Foods, Wens Foodstuff, Dekang Agriculture, Juxing Agriculture, Shennong Group, Tiankang Biological, and Tangrenshen [5] Animal Health - Demand for animal health products is on the rise, with significant year-on-year growth in various vaccines, such as a 30% increase for swine fever vaccines in July-August 2025 [5] - Companies like Keqian Biological and Ruipu Biological are highlighted for their strong internal growth potential due to new product launches [5] Poultry Farming - The price of white feather chickens has rebounded due to seasonal demand and tighter supply, with an average price of 6.92 CNY/kg as of September 19, 2025 [5] - The report notes a 17.66% year-on-year decrease in the number of breeding chickens updated in the first eight months of 2025, indicating potential long-term benefits for the white feather chicken industry [5] - Recommended companies include Shennong Development and Yisheng Livestock [5] Pet Food Sector - Domestic sales of pet food are driven by consumption upgrades and domestic substitution, with a reported growth rate of 11% across major e-commerce platforms from January to August 2025 [5] - The report highlights the introduction of new products and the strengthening of brand power among leading companies [5] - Recommended companies in the pet food sector include Guibao Pet, Zhongchong Co., Petty Co., and Lusi Co. [5]

Core Viewpoint - The stock price of Pulaike has experienced fluctuations, with a year-to-date increase of 8.94% but a recent decline over various trading periods, indicating potential volatility in the market [2]. Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, and sales of veterinary biological products, chemical drugs, and traditional veterinary medicine [2]. - The revenue composition of Pulaike includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2]. Financial Performance - For the first half of 2025, Pulaike achieved operating revenue of 559 million yuan, representing a year-on-year growth of 15.79%. The net profit attributable to the parent company was 116 million yuan, reflecting a significant increase of 57.12% [2]. - Since its A-share listing, Pulaike has distributed a total of 1.057 billion yuan in dividends, with 500 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Pulaike had 18,000 shareholders, an increase of 4.27% from the previous period. The average circulating shares per person decreased by 4.09% to 19,234 shares [2]. - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranks as the seventh largest, holding 3.4499 million shares, an increase of 141,400 shares from the previous period [3].

Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [1] Core Viewpoints - The report emphasizes the ongoing adjustment in the pig industry, highlighting the potential for value reassessment due to production capacity control and low-cost performance realization [3][16] - The poultry sector is expected to see improvements in fundamentals, with a focus on the white feather chicken breeding segment and price trends [4][29] - The animal health sector is witnessing a competitive landscape improvement and technological innovation, with several new products receiving clinical approval [5][37] - The pet economy is thriving, with domestic brands rapidly emerging, indicating sustained profitability improvements in the sector [9][59] Summary by Sections Pig Industry - Continuous deepening of pig price control measures is noted, with a focus on maintaining prices within a reasonable range [3][16] - Current average pig price is 13.15 yuan/kg, with a slight weekly decline [15] - Recommended companies include Muyuan Foods and Wens Foodstuffs, with ongoing recommendations for Juxing Agriculture and Shennong Group [3][16] Poultry Industry - The white feather chicken breeding segment shows potential for improvement, with significant updates in breeding stock [4][29] - Current prices for white feather chicken and related products are stable, with slight fluctuations noted [27][28] Animal Health Industry - The competitive landscape is improving, with notable profit differentiation among leading companies [5][36] - Several new vaccines have received clinical approval, marking significant advancements in the sector [5][37] Planting Industry - Prices for corn and soybean meal have shown a week-on-week decline, with ongoing commercialization of genetically modified seeds benefiting early adopters [7][42] Feed Industry - Feed prices are experiencing fluctuations, with a noted increase in production volume [8][48] - Recommended companies include Haida Group, with a focus on rising industry concentration [8][49] Pet Industry - The pet market is projected to reach 300.2 billion yuan in 2024, with a notable increase in consumer spending on pets [9][58] - Recommended companies in the pet food sector include Guobao Pet and Zhongchong Co., with a focus on the growing pet medical segment [9][59]

Core Points - The animal health sector experienced a decline of 0.36% on September 22, with Jinhe Biology leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance Summary - The following stocks in the animal health sector showed notable performance: - Shoufeng Holdings (002141) closed at 3.94, up 3.14% with a trading volume of 307,400 shares and a turnover of 118 million yuan [1] - ST Lvkang (002868) closed at 28.23, up 2.43% with a trading volume of 24,900 shares and a turnover of 69.04 million yuan [1] - Shengbiotech (600201) closed at 9.11, up 1.22% with a trading volume of 396,800 shares and a turnover of 364 million yuan [1] - Jinhe Biology (002688) closed at 6.74, down 2.18% with a trading volume of 234,800 shares and a turnover of 158 million yuan [2] - Other stocks such as Haili Biology (603718) and Zhongmu Co. (600195) also experienced declines of 1.43% and 1.39% respectively [1][2] Capital Flow Analysis - On that day, the animal health sector saw a net outflow of 53.34 million yuan from institutional investors, while retail investors contributed a net inflow of 67.06 million yuan [2]